PUBLISHER: Grand View Research | PRODUCT CODE: 1571556
PUBLISHER: Grand View Research | PRODUCT CODE: 1571556
China Lung Cancer Screening Market Size, Share & Trend Analysis Report By Cancer (Non-small Cell, Small Cell), By Diagnosis (Low Dose Spiral CT Scan), By End Use (Hospitals and Clinics), By Region, And Segment Forecasts, 2024 - 2030
China Lung Cancer Screening Market Growth & Trends:
The China lung cancer screening market size is anticipated to reach USD 1.04 billion by 2030 and is projected to grow at a CAGR of 11.09% during the forecast period, according to a new report by Grand View Research, Inc. This growth trajectory is driven by several pivotal factors, notably the high incidence and mortality rates of lung cancer in China. The National Library of Medicine reports that lung cancer was the most prevalent cancer in China in 2022, with approximately 1,060,600 new cases, outpacing colorectal cancer, which had 517,100 cases.
The high burden of lung cancer underscores the critical need for effective screening solutions. Advanced screening technologies, such as low-dose computed tomography (CT) scans, have revolutionized early detection, significantly improving survival rates by identifying cancers at earlier, more treatable stages. In addition, government initiatives, including the Healthy China 2030 plan, have expanded access to screening services, especially in rural and underserved areas, enhancing early detection and treatment capabilities.
Moreover, technological advancements in screening methodologies have significantly contributed to market growth. Low-dose computed tomography (LDCT) has emerged as a key tool in early lung cancer detection, offering superior sensitivity compared to traditional imaging techniques. LDCT's ability to detect lung cancer at an early stage has been instrumental in improving patient outcomes and reducing treatment costs. The increasing availability and affordability of advanced imaging technologies have made them more accessible to a broader population, further driving market expansion.
The market's growth is also supported by innovations in diagnostic tools, such as AI-enhanced imaging technologies, which improve the accuracy and efficiency of screenings. These advancements contribute to the broader adoption of screening programs and increased market demand. For instance, in March 2024, Alibaba Group's research division, DAMO Academy, introduced a new cancer screening tool in hospitals across China. This innovative AI-powered diagnostic tool, now operational in two hospitals in Zhejiang province, significantly accelerates the detection of various cancers. The device can analyze CT scans in under three minutes-one-third of the time required for manual examination by a physician. This advancement enhances both the speed and cost-effectiveness of cancer diagnosis, marking a significant leap forward in cancer screening technology.
China Lung Cancer Screening Market Report Highlights:
- Non-small cell lung cancer held the largest share of 81.29% in 2023, driven notably by the high prevalence, advancements in diagnostic technology, supportive government policies, and improvements in healthcare infrastructure
- On the basis of diagnosis, Low Dose Spiral CT (LDCT) Scan held the largest share of more than 70.0% in 2023 and it is also expected to grow at the fastest CAGR over the forecast period
- In 2023, diagnostic centers commanded the largest market share of 45.36% in the lung cancer screening sector. This dominance is attributed to their utilization of advanced imaging technologies, which provide high-resolution and accurate diagnostic capabilities
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Cancer
- 1.2.2. Diagnosis
- 1.2.3. End use
- 1.2.4. Regional Scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Cancer outlook
- 2.2.2. Diagnosis outlook
- 2.2.3. End use outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
Chapter 3. China Lung Cancer Screening Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. China Lung Cancer Screening Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- 3.3.1. Industry Analysis - Porter's
Chapter 4. China Lung Cancer Screening Market: Cancer Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. China Lung Cancer Screening Market: Cancer Movement Analysis
- 4.3. China Lung Cancer Screening Market by Cancer Outlook (USD Million)
- 4.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
- 4.5. Non-small Cell Lung Cancer (NSCLC)
- 4.5.1. Non-small Cell Lung Cancer (NSCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Small Cell Lung Cancer (SCLC)
- 4.6.1. Small Cell Lung Cancer (SCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. China Lung Cancer Screening Market: Diagnosis Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. China Lung Cancer Screening Market: Diagnosis Movement Analysis
- 5.3. China Lung Cancer Screening Market by Diagnosis Outlook (USD Million)
- 5.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
- 5.5. Low Dose Spiral CT Scan
- 5.5.1. Low Dose Spiral CT Scan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Chest X-ray
- 5.6.1. Chest X-ray Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. China Lung Cancer Screening Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. China Lung Cancer Screening Market: End Use Movement Analysis
- 6.3. China Lung Cancer Screening Market by End Use Outlook (USD Million)
- 6.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the following
- 6.5. Hospitals and Clinics
- 6.5.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. Diagnostic Centers
- 6.6.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Market Participant Categorization
- 7.2. Key Company Profiles
- 7.2.1. Biodesix
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. DELFI Diagnostics, Inc.
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. GE HealthCare
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. Siemens Healthineers AG
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. Koninklijke Philips N.V.
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. CANON MEDICAL SYSTEMS CORPORATION
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. Medtronic
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives
- 7.2.9. Shanghai United Imaging Healthcare Co., LTD
- 7.2.9.1. Company overview
- 7.2.9.2. Financial performance
- 7.2.9.3. Product benchmarking
- 7.2.9.4. Strategic initiatives
- 7.2.10. Freenome Holdings, Inc.
- 7.2.10.1. Company overview
- 7.2.10.2. Financial performance
- 7.2.10.3. Product benchmarking
- 7.2.10.4. Strategic initiatives
- 7.2.1. Biodesix
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 China lung cancer screening market, by cancer, 2018 - 2030 (USD Million)
- Table 4 China lung cancer screening market, by diagnosis, 2018 - 2030 (USD Million)
- Table 5 China lung cancer screening market, by end use, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Information procurement
- Fig. 2 Primary research pattern
- Fig. 3 Market research approaches
- Fig. 4 Value chain-based sizing & forecasting
- Fig. 5 Market formulation & validation
- Fig. 6 China lung cancer screening market segmentation
- Fig. 7 Market driver analysis (current & future impact)
- Fig. 8 Market restraint analysis (current & future impact)
- Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
- Fig. 10 Porter's five forces analysis
- Fig. 11 China lung cancer screening market, cancer outlook key takeaways (USD Million)
- Fig. 12 China lung cancer screening market: cancer movement analysis 2023 & 2030 (USD Million)
- Fig. 13 Non-small Cell Lung Cancer (NSCLC) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 14 Small Cell Lung Cancer (SCLC) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 15 China lung cancer screening market, diagnosis outlook key takeaways (USD Million)
- Fig. 16 China lung cancer screening market: diagnosis movement analysis 2023 & 2030 (USD Million)
- Fig. 17 Low dose spiral CT scan market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 18 Chest x-ray market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 19 China lung cancer screening market, end use outlook key takeaways (USD Million)
- Fig. 20 China lung cancer screening market: end use movement analysis 2023 & 2030 (USD Million)
- Fig. 21 Hospitals and clinics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 22 Diagnostic centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 23 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 24 List of key emerging company's/type disruptors/innovators
